CLS B Clinical Laserthermia Systems AB

CLS Americas Continues Clinical Collaborations from New West Coast Office at Spectrum Office Plaza in Irvine, CA

CLS Americas Continues Clinical Collaborations from New West Coast Office at Spectrum Office Plaza in Irvine, CA

Ideal Location for the Developer of High Precision, Image-Guided Laser Ablation System for Prostate Cancer Treatments

IRVINE, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- (publ) (CLS), today announced it has relocated its U.S. headquarters to a new office in the Irvine Spectrum Office Plaza located at 15707 Rockfield Blvd in the East Industrial Complex neighborhood in Irvine, CA. The medical device company develops high precision, image-guided laser ablation systems for minimally invasive treatment of prostate cancer tumors and soft tissue conditions.

“From our new office location, which is ideal for our current business, we look forward to our continued collaborations with clinical partners to provide safe and effective, minimally invasive treatments for prostate cancer and other tumors,” said Michael Magnani, managing director of CLS Americas. “This year will mark several important company milestones as we expand our product portfolio and introduce significant feature enhancements to our high precision, image-guided laser ablation system.”

CLS workstation and single-use accessories are designed and developed for image-guided, high precision soft tissue thermal therapy and laser ablation of tumors. The system includes a desk-top mobile laser unit, thermometry software for real-time temperature mapping of MRI images during treatments, and non-cooled laser applicators and single use devices.

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® |Thermal Therapy System including specially designed sterile disposable products for the minimally invasive ablative treatments of soft tissues and cancerous tumors, in accordance with regulatory approvals in EU and USA. The products are marketed for image-guided laser ablation (FLA, LITT) and for treatment with imILT®, the company’s interstitial thermotherapy with a potentially immune stimulating effect. CLS is headquartered in Lund, Sweden and has subsidiaries in Germany and Irvine, CA. CLS is listed on Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser (CA) is FNCA Sweden AB, Ph: 9. E-mail:  . Further information is available on .

The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) or its Thermoguide thermometry software by the Food and Drug Administration (FDA) in the United States of America (USA). 



Company Contact: 
CLS Americas:
Michael Magnani, Managing Director 
T:  
E:  

Media Contact:
TopSpin Communications
Joe Waldygo, President
P:   
E:  
EN
14/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clinical Laserthermia Systems AB

 PRESS RELEASE

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Acc...

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center CLS’s Single-Use, Sterile Instruments to be used in Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) --  (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its  accessories. This order of includes introducers,...

 PRESS RELEASE

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat P...

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation High Precision System Uses Image Guidance to Target Tumor, Preserve Healthy Tissue & Reduce Risks of Complications such as ED LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that , located in Vero Beach, Florida, will begin using the to treat prostate cancer patients. The TRANBERG system is designed to work with multiple image guidance systems for precise and...

 PRESS RELEASE

CLS Americas Selects Quest International to Provide Aftermarket Servic...

CLS Americas Selects Quest International to Provide Aftermarket Service and Logistics Operations for TRANBERG Laser Ablation System CLS Partners with World Class Aftermarket Services Company to Meet Strong Growth and Maximize Market Penetration LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has selected , a global aftermarket technical service provider to OEMs, to provide Service and Logistics Operations for the US market. Under the agreement, Quest will provide end to end w...

 PRESS RELEASE

CLS Americas States KASRAEIAN Urology will use TRANBERG Laser to Treat...

CLS Americas States KASRAEIAN Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation CLS’s New Mobile Service Program Enables Urologists to Provide Minimally Invasive, Image-guided, Laser Ablation Treatments to Patients without Capital Expenditure LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that located in Jacksonville, FL, will begin treating prostate cancer patients using the to provide focal laser ablation treatments. Operating under...

 PRESS RELEASE

CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical St...

CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System Minimally Invasive, Outpatient Treatment Provides High Precision Laser Focal Therapy of Prostate Tumors in an ASC LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch